Correlation between serum pro inflammatory cytokines and clinical scores of knee osteoarthritic patients using resveratrol as a supplementary therapy with meloxicam

Marouf BH, Hussain SA, Ali ZS · Indian Journal of Pharmacology

The mechanism did not line up with the claimed effect: correlations between falling inflammatory biomarkers and improving clinical scores were weak and nonsignificant across all tools (KOOS, WOMAC, VAS) — the cohort's own data do not connect its anti-inflammatory story to its symptom result.

Population

Secondary analysis of the same Sulaimani resveratrol-meloxicam cohort: 50 resveratrol and 32 placebo completers

Intervention

Correlation of changes in TNF-alpha, IL-1beta and IL-6 with changes in KOOS, WOMAC and VAS over the 90-day trial

Comparator

n/a (within-cohort correlation analysis)

Limitations

Secondary analysis of an already-questioned cohort; the companion paper analysed 42 placebo completers and this one 32. The cytokine falls it calls remarkable are small in its own table: IL-1beta 1.16 to 1.13 ng/L and IL-6 79.6 to 75.1. Correlations unadjusted for age, gender and body weight (the authors say so). No funding beyond the University of Sulaimani PhD project; no conflicts declared.